Investing.com - Unicycive Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations. Unicycive Therapeutics...
Unicycive Therapeutics, Inc. (UNCY) reported Q3 EPS of ($0.37), $0.09 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $951 thousand.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
|Average||9.38 (+1,202.78% Upside)|
|No. of Analysts||3|